Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2024 Dec 27

PMID 39729211

Authors

Maria Faltinova

Leena Vehmanen

Heli Lyytinen

Hanna Savolainen-Peltonen

Anni Virtanen

Mikko Haanpaa

Esa Hamalainen

Aila Tiitinen

Johanna Mattson

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to analyze changes in serum estradiol (E2) levels during concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast cancer (BC) patients with vulvovaginal atrophy (VVA). Secondary objectives included assessing the effects of therapy on vaginal atrophy, quality of life (QoL) and menopause-related symptoms.

Methods: 20 postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks. Gynecologic examination and symptom screening were conducted at baseline and after 12 weeks. Serum E2 levels were analyzed at baseline, and at two, four, eight, and 12 weeks. E2 levels were measured using both a routine liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and a highly sensitive (hsE2-MS) LC-MS/MS method.

Results: At baseline, serum E2 levels, measured with hsE2-MS, were below the lower limit of quantification (LLOQ) in all patients. E2 remained below LLOQ throughout the treatment period in three patients (15%). Persistent E2 elevation above LLOQ was observed in six patients (30%), while isolated E2 elevations occurred in 10 patients (50%). One patient experienced transient E2 elevation in two sporadic measurements. Serum E2 variations were shown by using both LC-MS/MS methods. Vaginal pH, vaginal maturation index (VMI), and VVA symptoms significantly improved during treatment.

Conclusion: Intravaginal estradiol therapy (10ug) during adjuvant letrozole resulted in transient increases in systemic E2 levels among early BC patients with VVA. Highly sensitive LC-MS/MS is a promising method for monitoring E2 levels during aromatase inhibitor (AI) therapy.

References

Burstein H, Lacchetti C, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 37(5):423-438. DOI: 10.1200/JCO.18.01160. View

Bekes I, Huober J . Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and Perspectives. Cancers (Basel). 2023; 15(16). PMC: 10453164. DOI: 10.3390/cancers15164190. View

Ganz P, Rowland J, Desmond K, Meyerowitz B, Wyatt G . Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998; 16(2):501-14. DOI: 10.1200/JCO.1998.16.2.501. View

Cella D, Fallowfield L . Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2007; 107(2):167-80. DOI: 10.1007/s10549-007-9548-1. View

Chirgwin J, Giobbie-Hurder A, Coates A, Price K, Ejlertsen B, Debled M . Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol. 2016; 34(21):2452-9. PMC: 4962733. DOI: 10.1200/JCO.2015.63.8619. View

Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M . Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?. Oncologist. 2008; 13(3):222-31. DOI: 10.1634/theoncologist.2007-0234. View

Santen R, Pinkerton J, Conaway M, Ropka M, Wisniewski L, Demers L . Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. 2002; 9(3):179-87. DOI: 10.1097/00042192-200205000-00006. View

Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M . Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010; 26(6):404-12. DOI: 10.3109/09513591003632258. View

Bachmann G, Lobo R, Gut R, Nachtigall L, Notelovitz M . Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008; 111(1):67-76. DOI: 10.1097/01.AOG.0000296714.12226.0f. View

10.

NOTELOVITZ M, Funk S, Nanavati N, Mazzeo M . Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002; 99(4):556-62. DOI: 10.1016/s0029-7844(01)01385-0. View

11.

Agrawal P, Singh S, Able C, Dumas K, Kohn J, Kohn T . Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer. Obstet Gynecol. 2023; 142(3):660-668. DOI: 10.1097/AOG.0000000000005294. View

12.

Cold S, Cold F, Jensen M, Cronin-Fenton D, Christiansen P, Ejlertsen B . Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. J Natl Cancer Inst. 2022; 114(10):1347-1354. PMC: 9552278. DOI: 10.1093/jnci/djac112. View

13.

Le Ray I, DellAniello S, Bonnetain F, Azoulay L, Suissa S . Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012; 135(2):603-9. DOI: 10.1007/s10549-012-2198-y. View

14.

McVicker L, Labeit A, Coupland C, Hicks B, Hughes C, McMenamin U . Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol. 2023; 10(1):103-108. PMC: 10623297. DOI: 10.1001/jamaoncol.2023.4508. View

15.

Kendall A, Dowsett M, Folkerd E, Smith I . Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006; 17(4):584-7. DOI: 10.1093/annonc/mdj127. View

16.

Sulaica E, Han T, Wang W, Bhat R, Trivedi M, Niravath P . Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. 2016; 157(2):203-210. DOI: 10.1007/s10549-016-3827-7. View

17.

Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M . Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012; 8(3):144-8. PMC: 3396801. DOI: 10.1200/JOP.2011.000352. View

18.

Pearson A, Chen J, Dhillon H, Kiely B . Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review. Breast Cancer Res Treat. 2024; 206(2):215-226. PMC: 11182841. DOI: 10.1007/s10549-024-07364-0. View

19.

Savolainen-Peltonen H, Hautamaki H, Tuomikoski P, Ylikorkala O, Mikkola T . Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy. Menopause. 2013; 21(7):732-9. DOI: 10.1097/GME.0000000000000120. View

20.

Faltinova M, Vehmanen L, Lyytinen H, Haanpaa M, Hamalainen E, Tiitinen A . Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. Breast Cancer Res Treat. 2021; 187(3):769-775. DOI: 10.1007/s10549-021-06168-w. View